III. Tissue oxygenation, fluid and hypothermia

R13 Tissue oxygenation
- A target systolic blood pressure of 80-90 mmHg should be employed until major bleeding has been stopped in the initial phase following trauma without brain injury. A mean arterial pressure 60-70 mmHg should be maintained in patients with combined haemorrhagic shock and severe traumatic brain injury.

R14 Fluid therapy
- Fluid therapy should be initiated and crystalloids applied initially to treat the hypotensive bleeding trauma patient. Hypotonic solutions such as Ringer’s lactate should be avoided in patients with severe head trauma. If colloids are administered, they should be used within the prescribed limits for each solution. Hypertonic solutions may be used during initial treatment and in haemodynamically unstable patients with penetrating torso trauma.

R15 Vasopressors and inotropic agents
- Vasopressors may be administered to maintain target arterial pressure in the absence of a response to fluid therapy and inotropic agents may be infused in the presence of myocardial dysfunction.

R16 Temperature management
- Early application of measures to reduce heat loss and warm the hypothermic patient should be employed to achieve and maintain normothermia. Hypothermia at 33-35°C for 24 h may be applied in patients with traumatic brain injury once bleeding and other sources have been controlled.

R17 Erythrocytes
- Treatment should aim to achieve a target Hb of 7-9 g/dl.

IV. Rapid control of bleeding

R18 Early abdominal bleeding control
- Early abdominal bleeding control should be achieved using packing, direct surgical bleeding control and local haemostatic procedures; aortic cross clamping may be employed as adjunct bleeding control in the exsanguinating patient.

R19 Pelvic ring closure & stabilisation
- Patients with pelvic ring disruption in haemorrhagic shock should undergo immediate pelvic ring closure and stabilisation.

R20 Packing, embolisation & surgery
- Patients with ongoing haemodynamic instability despite adequate pelvic ring stabilisation should undergo early preperitoneal packing, angiographic embolisation and/or surgical bleeding control.

R21 Damage control surgery
- Damage control surgery should be employed in the severely injured patient presenting with deep haemorrhagic shock, signs of ongoing bleeding and coagulopathy. Severe coagulopathy, hypothermia, acidosis, inaccessible major anatomic injury, a need for time-consuming procedures or concomitant major injury outside the abdomen should also trigger a damage control approach. Primary definitive surgical management should be employed in the haemodynamically stable patient in the absence of any of these factors.

R22 Local haemostatic measures
- Topical haemostatic agents should be employed in combination with other surgical measures or with packing for venous or moderate arterial bleeding associated with parenchymal injuries.

R23 Coagulation support
- Monitoring and measures to support coagulation should be initiated as early as possible.

R24 Antifibrinolytic agents
- Tranexamic acid should be administered as early as possible to the trauma patient who is bleeding or at risk of significant haemorrhage at a loading dose of 1 g infused over 10 min, followed by an intravenous infusion of 1 g over 8 h. Tranexamic acid should be administered to the bleeding trauma patient within 3 h after injury. Protocols for the management of bleeding patients may consider administration of the first dose of tranexamic acid en route to the hospital.

R25 Calcium
- Ionised calcium levels should be monitored and maintained within the normal range during massive transfusion.

R26 Plasma
- Plasma or fibrinogen should be administered initially in patients with massive bleeding. If further plasma is administered, an optimal plasma:red blood cell ratio may be at least 1:2. Plasma transfusion should be avoided in patients without substantial bleeding.

R27 Fibrinogen & cryoprecipitate
- Fibrinogen concentrate or cryoprecipitate should be administered if significant bleeding is accompanied by thromboelastographic signs of a functional fibrinogen deficit or a plasma fibrinogen level of less than 1.5-2.0 g/L; an initial fibrinogen dose of 3-4 g or 50 mg/kg of cryoprecipitate, approximately equivalent to 15-20 single donor units in a 70 kg adult, may be employed. Repeat doses may be guided by viscoelastic monitoring and laboratory assessment of fibrinogen levels.

R28 Platelets
- Platelets should be administered to maintain a platelet count above 50 x 10^9/L. A platelet count above 100 x 10^9/L in patients with ongoing bleeding and/or traumatic brain injury may be maintained. An initial dose of 4-8 platelet concentrates or one aphaeresis pack may be used.

R29 Antiplatelet agents
- Platelets may be administered in patients with substantial bleeding or intracranial haemorrhage who have been treated with antiplatelet agents. Desmopressin (0.3 µg/kg) may be administered if the patient has been treated with acetylsalicylic acid alone. Platelet function may be measured in patients treated or suspected of being treated with antiplatelet agents. Platelet concentrates may be used if platelet dysfunction is documented in a patient with continued microvascular bleeding.

R30 Desmopressin
- Desmopressin (0.3 µg/kg) may be administered in patients treated with platelet inhibiting drugs or with von Willebrand disease. Desmopressin may not be administered routinely in the bleeding trauma patient.

R31 Prothrombin complex concentrate
- Prothrombin complex concentrate (PCC) should be used early for the emergency reversal of vitamin K-dependent oral anticoagulants. PCC may be administered in the bleeding patient with thromboelastographic evidence of delayed coagulation initiation if a concentrate-based goal-directed strategy is applied.

R32 Novel anticoagulants
- Substrate-specific anti-factor Xa activity may be measured in patients treated or suspected of being treated with oral anti-factor Xa agents such as rivaroxaban, apixaban or edoxaban. Reversal may be achieved with high-dose (25-50 U/kg) PCC if bleeding is life-threatening. PCC may not be administered in patients treated or suspected of being treated with oral direct thrombin inhibitors such as dabigatran.

R33 Recombinant activated coagulation factor VII
- Treatment with recombinant activated coagulation factor VIIa (rFVIIa) may be considered if major bleeding and traumatic coagulopathy persist despite standard attempts to control bleeding and best-practice use of conventional haemostatic measures. rFVIIa may not be used in patients with intracranial haemorrhage caused by isolated head trauma.

R34 Thromboprophylaxis
- Mechanical thromboprophylaxis with intermittent pneumatic compression and/or anti-embolic stockings may be applied as soon as possible. Pharmacological thromboprophylaxis should be employed within 24 h after bleeding has been controlled. Inferior vena cava filters as thromboprophylaxis should not be routinely employed.